Take a look at what our portfolio companies accomplished in January 2024:
IMVARIA Announces FDA De Novo Marketing Authorization of Fibresolve and the Adoption of Novel CPT Billing Codes by the American Medical Association
The FDA authorization of IMVARIA’s lead product Fibresolve, as a billable digital diagnostic tool for clinicians to use for patients, will expedite the medical community’s access to a non-invasive diagnostic solution using digital biomarkers in a novel way for lung fibrosis. This new authorization builds on the past medical and scientific assessments that the FDA had previously completed in assigning Fibresolve Breakthrough Device Designation.
